Data from Pharmawand - Curated by Marshall Pearce - Date added 05 December 2017

Treatment of a HIV infected lung cancer patient with Opdivo (nivolumab) by physicians at the Pitie Salpetriere Hospital showed a huge decrease in the patient’s viral “reservoirs”— areas in the body that allow HIV to escape from antiretroviral treatments. The discovery could lead to a new method for dealing with viral reservoirs, which have proven to be one of the biggest hurdles to developing HIV cures and vaccines. These reservoirs contain latent HIV-infected cells that can reawaken at any time, making it impossible to eradicate the virus for good. The treatment was reported by a letter to the Annals of Oncology.

See-"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer"- A Guihot A -G Marcelin M -A Massiani A Samri C Soulié B Autran J -P Spano.- Annals of Oncology, mdx696,

Published: 01 December 2017.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.



Essential screening, diagnosis and best strategies to manage bedwetting.

+ 7 more

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Type 2 Diabetes

Type 2 Diabetes

View the latest epidemiology data, patient perspectives, ADA and EASD recommendations, treatment options and more.

Load more

Related Content